Article first published as Israeli Cancer Vaccine ‘Coming Soon’ on Technorati.
Vaxil BioTherapeutics, a biotechnical company based in Ness Ziona, near Tel Aviv, Israel has produced a ground-breaking therapeutic vaccine for cancer patients which could prevent about 90% of cancers from coming back.
Vaxil was founded in 2006 by Dr. Lior Carmon and the vaccine is now in clinical trials at the Hadassah University Medical Centre in Jerusalem. The vaccine could be available as early as 2017 to administer on a regular basis, not only to help treat cancer but in order to keep the disease from recurring.
The vaccine is being tested against a type of blood cancer, ‘multiple myeloma’. If the substance works as hoped, its platform technology, VaxHit could be applied to 90% of all known cancers, including prostate and breast cancer, solid and non-solid tumours.
“In cancer, the body knows something is not quite right but the immune system doesn’t know how to protect itself against the tumour like it does against an infection or virus. This is because cancer cells are the body’s own cells gone wrong,” says Julian Levy, the company’s CFO. “Coupled with that, a cancer patient has a depressed immune system, caused both by the illness and by the treatment.”
The trick is to activate a compromised immune system to mobilize against the threat.
‘a vaccine that works like a drug’
A traditional vaccine helps the body’s immune system fend off foreign invaders such as bacteria or viruses, and is administered to people who have not yet had the ailment. Therapeutic vaccines, like the one Vaxil has developed, are given to sick people, and work more like a drug.
Vaxil’s lead product, ImMucin, activates the immune system by “training” T-cells –– the immune cells that protect the body by searching out and destroying cells that display a specific molecule (or marker) called MUC1. MUC1 is typically found only on cancer cells and not on healthy cells. The T-cells don’t attack any cells without MUC1, meaning there are no side effects unlike traditional cancer treatments. More than 90% of different cancers have MUC1 on their cells, which indicates the potential for this vaccine.
“It’s a really big thing,” says Levy, a biotechnology entrepreneur who was formerly CEO for Biokine Therapeutics. “If you give chemo, apart from the really nasty side effects, what often happens is that cancer becomes immune [to it]. The tumour likes to mutate and develops an ability to hide from the treatment. Our vaccines are also designed to overcome that problem.”
ImMucin is foreseen as a long-term strategy — a shot every few months, with no side effects — to stop the cancer from recurring after initial treatments, by ensuring that the patient’s own immune system keeps it under control.
In parallel, the company is also working on a vaccine that treats tuberculosis, a disease that’s increasing worldwide, including in the developed world, and for which the current vaccine is often ineffective and treatment is problematic.
Two of my dearest late friends had their cancers stalled for some years by wonderful therapies and now a much-loved cousin is overjoyed about the news from Vaxil. Heaven willing she will still enjoy its benefits in 20 years’ time!
msniw
No comments:
Post a Comment